Recent loosening of legal restrictions on cannabis and its chemical constituents, including phytocannabinoids such as Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), has led to rapid proliferation and wide availability of products containing CBD. Although using pure CBD does not result in THC-like intoxication, it is not risk-free. In this review, we examine CBD from scientific, marketing, and regulatory perspectives. Specifically, we evaluate the evidence used to support statements concerning CBD’s real and putative medical effects and discuss misleading information that has been used in marketing approaches. Also, we explore the current legal landscape surrounding CBD. We conclude that further research is necessary to clarify legitimate therapeutic effects of CBD. Federal regulation is also necessary to assure quality, safety, and efficacy of CBD products. Until new regulations are enacted to ensure purity and label accuracy, consumers should balance any perceived benefits of CBD use against potential risks associated with using products of unknown quality.
By Jenny L. Wiley, Camille Kempf Gourdet, Brian F. Thomas.
April 2020 Open Access Peer Reviewed
Wiley, J. L., Gourdet, C. K., & Thomas, B. F. (2020). Cannabidiol: Science, marketing, and legal perspectives. RTI Press. RTI Press Publication No. OP-0065-2004 https://doi.org/10.3768/rtipress.2020.op.0065.2004
© 2021 RTI International. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.